Anticancer Research · 2021 · 27 citations · 21 references
MedicineOncologyGastrointestinal OncologyNeoplasiaSurvival AnalysisCancer Survival AnalysisMalignant NeoplasmsAspartate Aminotransferase ElevationColorectal Cancer PrognosisDisease-free Survival AnalysisDisease-free Survival AssessmentPrognostic Factors AnalysisPrognostic Marker AssessmentPrognostic Marker EvaluationSerum Alanine Aminotransferase
BACKGROUND/AIM: The Aspartate aminotransaminase/Alanine aminotransaminase ratio (AST/ALT ratio) has been identified as a prognostic marker for several malignancies. In this study, we evaluated the prognostic value of the AST/ALT ratio in a large cohort of non-metastatic colorectal cancer patients (CRC). PATIENTS AND METHODS: A total of 536 patients with stage II and III CRC, as well as available AST/ALT ratio were included in this single-center retrospective analysis. Laboratory data were measured within two weeks before histological tumor diagnosis. Co-Primary endpoints for this analysis were disease-free survival (DFS) and overall survival (OS). RESULTS: In univariate cox regression DFS was significantly shorter in patients with an elevated AST/ALT ratio (HR=1.568, 95%CI=1.10-2.23, p=0.012). In multivariable analysis, the prognostic association between an elevated AST/ALT ratio and a poor survival prevailed statistically significant (HR=1.53, 95%C=1.05-2.22, p=0.026). No statistically significant association between the AST/ALT ratio and OS was observed (HR=1.4, 95% CI=0.89-2.22, p=0.14). CONCLUSION: In this study, the serum AST/ALT ratio emerged as a valid prognostic marker for DFS in non-metastatic colorectal cancer patients at stage II and III.
21
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
THE METABOLISM OF TUMORS IN THE BODY
Otto Warbürg, Franz Wind, Erwin Negelein · The Journal of General Physiology · 1927 · 4.4K citations · Full text
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André, C. Boni, Lamia Mounedji-Boudiaf et al. · New England Journal of Medicine · 2004 · 3.7K citations · Full text
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Chris Twelves, A. Wong, Marek P. Nowacki et al. · New England Journal of Medicine · 2005 · 1.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
J. Philip Kuebler, H. Samuel Wieand, Michael J. O’Connell et al. · Journal of Clinical Oncology · 2007 · 1.1K citations · Full text